Literature DB >> 20122677

Liver transplantation is an alternative treatment of hepatocellular carcinoma beyond the Milan criteria.

Hsiu-Lung Fan1, Teng-Wei Chen, Chung-Bao Hsieh, Hsiang-Chun Jan, Sheng-Chuan His, Chan De-Chuan, Chi-Hong Chu, Jyh-Cherng Yu.   

Abstract

BACKGROUND: The decision to perform liver transplantation (LT) or liver resection (LR) for patients with hepatocellular carcinoma (HCC) who are beyond the Milan criteria remains controversial.
METHODS: We retrospectively analyzed outcome data for 179 patients with HCC beyond the Milan criteria who were treated with LR (n = 135) or LT (n = 44). Univariate and multivariate Cox proportional hazard models were established. Kaplan-Meier survival curves were generated, and a log-rank test was performed to compare group survival status.
RESULTS: Patients who underwent LR group were significantly older, had a lower TNM stage, and were more likely to have unilateral disease and noncirrhotic liver. Significantly more patients in the LR group had recurrence (53.3% vs 29.5%) or died (61.5% vs 43.2%) than patients in the LT group. Recurrence-free survival rates were 11.9% for the LR group and 61.5% for the LT group. The median overall survival duration showed no statistically difference between the LR group (28.0 months) and the LT group (50.0 months).
CONCLUSIONS: LT may be the better choice for patients with HCC beyond the Milan criteria. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20122677     DOI: 10.1016/j.amjsurg.2009.07.049

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  6 in total

1.  Building a comprehensive genomic program for hepatocellular carcinoma.

Authors:  Theresa R Harring; Jacfranz J Guiteau; N Thao T Nguyen; Ron T Cotton; Marie-Claude Gingras; David A Wheeler; Christine A O'Mahony; Richard A Gibbs; F Charles Brunicardi; John A Goss
Journal:  World J Surg       Date:  2011-08       Impact factor: 3.352

2.  Effective hepatic artery chemoembolization for advanced hepatocellular carcinoma with multiple tumor thrombi and pulmonary metastases: A case report.

Authors:  De-Jia Huang; Yan-Hao Li; Yao-Chang Luo; Jun-Zhen Huang; Hai-Yuan He
Journal:  Oncol Lett       Date:  2016-07-12       Impact factor: 2.967

3.  Resection or Transplant in Early Hepatocellular Carcinoma.

Authors:  Markus B Schoenberg; Julian N Bucher; Adrian Vater; Alexandr V Bazhin; Jingcheng Hao; Markus O Guba; Martin K Angele; Jens Werner; Markus Rentsch
Journal:  Dtsch Arztebl Int       Date:  2017-08-07       Impact factor: 5.594

4.  Long-term survival after chemoembolization of metastatic right atrial tumor thrombus as a presenting feature of hepatocellular carcinoma: A case study.

Authors:  Jun-Hui Sun; Yue-Lin Zhang; Chun-Hui Nie; Li-Ming Chen; Jian-DI He; Wei-Lin Wang; Shu-Sen Zheng
Journal:  Oncol Lett       Date:  2012-02-28       Impact factor: 2.967

5.  MicroRNA-182 downregulates metastasis suppressor 1 and contributes to metastasis of hepatocellular carcinoma.

Authors:  Jian Wang; Jingwu Li; Junling Shen; Chen Wang; Lili Yang; Xinwei Zhang
Journal:  BMC Cancer       Date:  2012-06-08       Impact factor: 4.430

6.  Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.

Authors:  Chieh-Lin Teng; Wen-Li Hwang; Yi-Ju Chen; Kuang-Hsi Chang; Shao-Bin Cheng
Journal:  World J Surg Oncol       Date:  2012-02-17       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.